KRAS G12C Mutation Is Associated with Increased Risk of Recurrence in Surgically Resected Lung Adenocarcinoma.

doi:10.1158/1078-0432.CCR-20-4772

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

KRAS G12C Mutation Is Associated with Increased Risk of Recurrence in Surgically Resected Lung Adenocarcinoma.

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 May 2021

Jones Gregory D, Caso Raul, Tan Kay See, Mastrogiacomo Brooke, Sanchez-Vega Francisco, Liu Yuan, Connolly James G, Murciano-Goroff Yonina R, Bott Matthew J, Adusumilli Prasad S, Molena Daniela, Rocco Gaetano, Rusch Valerie W, Sihag Smita, Misale Sandra, Yaeger Rona, Drilon Alexander, Arbour Kathryn C, Riely Gregory J, Rosen Neal, Lito Piro, Zhang Haiying, Lyden David C, Rudin Charles M, Jones David R, Li Bob T, Isbell James M

Abstract excerpt

PURPOSE: KRAS G12C is the most common KRAS mutation in primary lung adenocarcinoma. Phase I clinical trials have demonstrated encouraging clinical activity of KRAS G12C inhibitors in the metastatic setting. We investigated disease-free survival (DFS) and tumor genomic features in patients with surgically resected KRAS G12C-mutant lung adenocarcinoma. EXPERIMENTAL DESIGN: Patients who underwent resection of stage...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma of Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Amino Acid Substitution

Share to Biomarkers, Tumor

Share to Neoplasm Staging

Share to Proto-Oncogene Proteins p21(ras)

Share to Recurrence

Share to Survival Analysis

Share to Treatment Outcome

Source

Open in PubMed Open full text

Identifiers

PMID: 33593884
DOI: 10.1158/1078-0432.CCR-20-4772
PMCID: PMC8102372

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

KRAS G12C Mutation Is Associated with Increased Risk of Recurrence in Surgically Resected Lung Adenocarcinoma.PMID 33593884Read ↗

KRAS-G12C mutation is associated with poor outcome in surgically resected lung adenocarcinoma.Semantic proximity Read ↗

Prognostic Impact and Recurrence Pattern of KRAS G12C Mutation in Surgically Resected Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Prognostic value of KRAS G12C mutation in lung adenocarcinoma stratified by stages and radiological features.Semantic proximity Read ↗

KRAS G12C mutation and risk of disease recurrence in stage I surgically resected lung adenocarcinoma.Semantic proximity Read ↗

Clinicopathologic features of KRAS G12C-mutated non-small cell lung carcinomas:insights from 279 retrospective cases.Semantic proximity Read ↗

Real world outcomes in KRAS G12C mutation positive non-small cell lung cancer.Semantic proximity Read ↗

Prognostic value of the KRAS G12V mutation in 841 surgically resected Caucasian lung adenocarcinoma cases.Semantic proximity Read ↗

Prognostic value of KRAS G12V mutation in lung adenocarcinoma stratified by stages and radiological features.Semantic proximity Read ↗

Clinicopathologic features, concurrent genomic alterations, and clinical outcomes of patients with KRAS G12D mutations in resected lung adenocarcinoma.Semantic proximity Read ↗

KRAS G12C in advanced NSCLC: Prevalence, co-mutations, and testing.Semantic proximity Read ↗

Characterization of KRAS Mutation Subtypes in Non-small Cell Lung Cancer.Semantic proximity Read ↗

Distinct molecular subtypes of KRASG12C-mutant lung adenocarcinoma: Insights into clinical outcomes, tumour microenvironments and therapeutic strategies.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.